No Difference in Risk of Febrile Neutropenia Between Patients Receiving Pegfilgrastim Biosimilar vs Originator

In a real-world cohort of 2,045 patients with various cancers initiating myelosuppressive chemotherapy, investigators administered either originator pegfilgrastim or biosimilar pegfilgrastim within 3 days of chemotherapy completion. Study results indicated that there was no difference in febrile neutropenia risk after cycle 1 of chemotherapy detected in either patient population.

Access the full article to read more here.